Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NSE - Delayed Quote INR

Valiant Laboratories Limited (VALIANTLAB.NS)

Compare
80.62
-7.00
(-7.99%)
At close: February 28 at 3:29:59 PM GMT+5:30
Loading Chart for VALIANTLAB.NS
DELL
  • Previous Close 87.62
  • Open 89.35
  • Bid --
  • Ask --
  • Day's Range 79.70 - 89.35
  • 52 Week Range 79.70 - 174.85
  • Volume 148,958
  • Avg. Volume 144,390
  • Market Cap (intraday) 3.503B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.94
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.

valiantlabs.in

77

Full Time Employees

March 31

Fiscal Year Ends

Recent News: VALIANTLAB.NS

View More

Performance Overview: VALIANTLAB.NS

Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

VALIANTLAB.NS
27.45%
S&P BSE SENSEX
6.32%

1-Year Return

VALIANTLAB.NS
53.41%
S&P BSE SENSEX
1.24%

3-Year Return

VALIANTLAB.NS
50.28%
S&P BSE SENSEX
30.14%

5-Year Return

VALIANTLAB.NS
50.28%
S&P BSE SENSEX
91.13%

Compare To: VALIANTLAB.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VALIANTLAB.NS

View More

Valuation Measures

Annual
As of 2/28/2025
  • Market Cap

    3.49B

  • Enterprise Value

    3.45B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.30

  • Price/Book (mrq)

    1.51

  • Enterprise Value/Revenue

    3.25

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.90%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.06B

  • Net Income Avi to Common (ttm)

    -41.44M

  • Diluted EPS (ttm)

    -0.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.19B

  • Total Debt/Equity (mrq)

    49.90%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: VALIANTLAB.NS

View More

Company Insights: VALIANTLAB.NS

Research Reports: VALIANTLAB.NS

View More

People Also Watch